1 Immediate versus conditional treatment of uncomplicated urinary tract infection - a randomized-controlled comparative effectiveness study in general practices Abstract Background Ildikó Gágyor 1* * Corresponding author Eva Hummers-Pradier 1 Michael M Kochen 1 Guido Schmiemann 3 Karl Wegscheider 4 Jutta Bleidorn Department of General Practice and Family Medicine, University of Goettingen, Humboldtallee 38, Goettingen 37073, Germany 2 Institute of General Practice, Hannover Medical School, Carl-Neuberg-Str.1, Hannover 30625, Germany 3 Institute for Public Health and Nursing Research, Department for Health Services Research, University of Bremen, Grazer Str. 4, Bremen 28359, Germany 4 Department of Medical Biometry and Epidemiology, University Medical Centre Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany Uncomplicated urinary tract infections (UTI) are usually treated with antibiotics as recommended by primary care guidelines. Antibiotic treatment supports clinical cure in individual patients but also leads to emerging resistance rates in the population. We designed a comparative effectiveness study to investigate whether the use of antibiotics for uncomplicated UTI could be reduced by initial treatment with ibuprofen, reserving antibiotic treatment to patients who return due to ongoing or recurrent symptoms.
2 Methods/design This is a randomized-controlled, double-blind, double dummy multicentre trial assessing the comparative effectiveness of immediate vs. conditional antibiotic therapy in uncomplicated UTI. Women > 18 and < 65 years, presenting at general practices with at least one of the typical symptoms dysuria or frequency/urgency of micturition, will be screened and enrolled into the trial. During an 18- months recruitment period, a total of 494 patients will have to be recruited in 45 general practices in Lower Saxony. Participating patients receive either immediate antibiotic therapy with fosfomycin-trometamol 1x3g or initial symptomatic treatment with ibuprofen 3x400mg for 3 days. The ibuprofen group will be provided with antibiotic therapy only if needed, i.e. for persistent or worsening symptoms. For a combined primary endpoint, we choose the number of all antibiotic prescriptions regardless of the medical indication day 0 28 and the disease burden, defined as a weighted sum of the daily total symptom scores from day 0 to day 7. The study is considered positive if superiority of conditional antibiotic treatment with respect to the first primary endpoint and non-inferiority of conditional antibiotic treatment with respect to the second primary endpoint is proven. Discussion This study aims at investigating whether the use of antibiotics for uncomplicated UTI could be reduced by initial treatment with ibuprofen. The comparative effectiveness design was chosen to prove the effectiveness of two therapeutic strategies instead of the pure drug efficacy. Trial registration Clinicaltrials.Gov: NCT Keywords Urinary tract infection, Comparative effectiveness design, Antibiotic prescription, General practice Background Uncomplicated urinary tract infections (UTI) are a common condition in general practice. To date, they are usually treated with antibiotics, as recommended by primary care guidelines [1-3] - resulting in effective and fast symptom resolution. However, this approach accounts for a substantial number of antibiotic prescriptions in primary care with inherent disadvantages . The increasing use of antibiotics is the main reason for emerging resistance rates [5,6]. More than 20% of E.coli, the most common uropathogens, are resistant to trimethoprimsulfomethoxazole and to cephalosporins ; for fluoroquinolons the same trend can be observed. Since less antibiotic prescribing is associated with lower levels of antibiotic resistance [8,9], efforts should be made to reduce unnecessary prescriptions [10,11]. Up to now, only few randomized-controlled trials compared antibiotic treatment with placebo or different therapeutic strategies, i.e. empirical, targeted or delayed antibiotic treatment in uncomplicated UTI [12-14]. These trials suggested that in many cases uncomplicated UTI are
3 a self limiting condition. Results showed delayed symptomatic and bacteriological cure in the placebo and in the delayed prescription group, but no serious complications [4,7,12,14]. The failure rate in the placebo group due to symptom persistence/worsening was considered a strong argument in favour of antimicrobial treatment . In 2007/2008, the authors carried out a randomized controlled pilot trial comparing ibuprofen and ciprofloxacin in uncomplicated UTI with regard to symptom course Non-inferiority of ibuprofen could be demonstrated based on a sample size of 79 patients. Symptomatic treatment was sufficient for 66% (24/36) patients in the ibuprofen-group, with secondary antibiotic treatment rates of 33% (12/36) versus 18% (6/33) in the ibuprofen and ciprofloxacin groups respectively . In view of the symptomatic treatment as alternative treatment option for uncomplicated UTI, we designed a comparative effectiveness study with the aim to investigate whether the use of antibiotics for uncomplicated UTI could be reduced by initial treatment with ibuprofen, reserving antibiotic treatment to patients who return due to ongoing or recurrent symptoms. Our main research questions are: 1) Does conditional antibiotic use in patients with uncomplicated UTI reduce the number of antibiotic prescriptions without significant increase in symptoms or recurrent episodes/complications? 2) Is the proposed strategy safe in terms of complications and recurrences? Methods Design This is a randomized-controlled, double-blind, double dummy multicentre trial assessing the comparative effectiveness of immediate vs. conditional antibiotic therapy in uncomplicated UTI. Patients Inclusion criteria Women > 18 and < 65 years with suspected UTI, presenting at general practices with at least one of the typical symptoms dysuria or frequency/urgency of micturition. Written informed consent is required. Key exclusion criteria are any signs of complicated infection (temperature > 38 C, pain on renal bed percussion; any conditions that may lead to complicated infections (i.e. pregnancy, renal diseases, immunosuppressive therapy); current antibiotic therapy, current intake of NSAIDs, current intake of drugs interacting with the trial drugs (anticoagulants, corticosteroids) contraindications or allergies for trial drugs; renal diseases (renal failure; urinary tract abnormalities or past urinary surgery, urinary catheterization); history of gastrointestinal ulcers; serious neurological diseases (epilepsy, multiple sclerosis, paraplegia); disability to understand trial information. Setting and recruitment The trial will be carried out in general practices in northern Germany. A total of 494 patients will have to be recruited in 45 investigator sites (general practices) during an 18- months
4 recruitment period. Women presenting with UTI symptoms will be screened and enrolled by their GP. To achieve the recruitment goal as soon as possible, high emphasis will be put on structured practice support to optimize patient recruitment (i.e. newsletters, telephone calls, incentives). Intervention/trial drug Participating patients receive either immediate antibiotic therapy with fosfomycintrometamol 1x3g or initial symptomatic treatment with ibuprofen 3x400mg for 3 days. Antibiotic therapy will be only provided if needed, i.e. for persistent or worsening symptoms. Fosfomycin for oral treatment is only available as granules. Thus, a double-dummy-design is required with the intervention group taking placebo granule sachets 1x1 additional to 3x400 mg ibuprofen tablets and the control group taking placebo tablets 3x1/3 days additional to fosfomycin-trometamol. During the entire trial, long term medication or co-medication should be prescribed and taken as usual. Patients will be told to avoid taking spasmolytic drugs. Any further medication will be documented in Case Report Form (CRF). If secondary antibiotic treatment is required due to ongoing/worsening symptoms, antibiotics should be chosen in line with the results of the urine culture at day 0. In order to guarantee concealment a central randomization on patient level will be performed. Code numbers will be assigned from the random list to the drug units in blocks of six and distributed to the participating practices. At inclusion, the code number will be assigned and the drug package will be transferred to the patient by the GP. Procedures Day 0/inclusion Patients complete a symptom questionnaire and provide a urine specimen for culture, dipstick and pregnancy test. Temperature will be taken oral or auricular. The GP hands over the blinded trial drug and instructs the patient to reconsult in case of persistent or worsening symptoms, or in case of fever. In uncomplicated cases the number of mandatory study visits will be restricted to day 0. If the patient returns within three days with persistent or worsening symptoms of UTI, the study drug will be discontinued and replaced by an antibiotic at the discretion of the GP, chosen in line with urine culture results if available. Recurrent UTI after the end of the study treatment will be treated with antibiotics at the discretion of the GP. All urine cultures will be performed in one central laboratory. Native urine will be transported within 24 h to the laboratory; in the meantime it will be stored in the refrigerator. Data collection and management Inclusion Patients complete a piloted symptom questionnaire to score severity of each symptom (dysuria, frequency and low abdominal pain). Symptoms will be scored from 0 (not at all) to
5 4 (very strong), and symptom scores will be added to a maximal sum score of 12 points. The symptom questionnaire has already been piloted in the study HWI-01 in 79 patients. Additionally, patients will record the UTI-related impairment in daily live-activities by the Activity Impairment Assessment (AIA) . Demographic and clinical data and laboratory results will be documented by the practice staff in an internet-based database (ecrf). Follow up Further symptom assessment will be conducted via telephone interviews by the study nurses of the University Departments' research teams. Symptom related data and impairment in daily live-activities (AIA) will be scored according to the symptom questionnaire at inclusion. Additionally, cause, duration and dosage of any antibiotic prescriptions will be recorded, as well as adverse events. Telephone interviews will be conducted on day 1, 3, 5 and 7, or until resolution of symptoms. During this time, patients will complete a symptom diary daily to collect continuous data by telephone interviews.) The last telephone interview will take place on day 28. To complete follow-up data in terms of recurrences and safety information, further interviews will be conducted after 6 and 12 months (Figure 1). Figure 1 Study plan. Abbreviations: UTI= Urinary Tract Infection, AE= Adverse Event, SAE= Serious Adverse Event, AIA= Activity Impairment Assessment Outcomes Primary endpoints Two co-primary endpoints measuring number of antibiotic prescriptions and disease burden are considered. First co-primary endpoint Number of all antibiotic prescriptions regardless of the medical indication day Second co-primary endpoint The disease burden will be calculated as weighted sum of the daily total symptom scores from day 0 to day 7. The weights are chosen in a way that the measure represents the area under curve (AUC) below the total symptom score as a function of time. Key secondary endpoints Sum of daily defined doses (DDD) per patient; proportion of patients with/number of recurrent UTI episodes within 28 days/6/12 months, defined by the re-occurrence of UTI symptoms after symptom resolution; proportion of symptom-free patients at day 4 and 7; total disease burden (AUC) until day 4; disease burden related to each of the three symptoms until day 7; activity impairment assessment (AIA) day 1 to day 7; number of complications (febrile UTI, pyelonephritis/septic syndrome) and the number of adverse events.
6 The defined daily doses (DDD) are based on the official ATC-Index for Germany 2010 , which is derived from the WHO-index 2010 . Symptom-free is defined as a total symptom score of 0. Statistical analysis and reporting The primary analysis will be based on the results of two statistical tests. The first test (superiority) will be on the following two hypotheses with respect to the first co-primary endpoint: H0: The number of antibiotic prescriptions within the interval 0 28 days in the conditional use group is greater than or equal to the corresponding number in the immediate use group. vs. H1: The number of antibiotic prescriptions within the interval 0 28 days in the conditional use group is lower than the corresponding number in the immediate use group. The second test (non-inferiority) will be on the following two hypotheses with respect to the second co-primary endpoint: H0: The disease burden within the interval 0 7 days in the conditional use group is greater than or equal to 125% of the corresponding disease burden in the immediate use group. vs. H1: The disease burden within the interval 0 7 days in the conditional use group is less than 125% of the corresponding disease burden in the immediate use group. Since both criteria have to be fulfilled for the study being positive, the intersection hypothesis has to be proven. This can effectively be achieved by a closed testing procedure where both hypotheses are tested hierarchically at a level of 2.5% one-sided, i.e. the second hypothesis will only be tested if the first test was significant. Formally, hypothesis (i) will be tested non-parametrically using an exact Mann Whitney rank sum test since the distribution of antibiotic prescriptions will be discrete and is not expected to follow a known standard distribution. The test will be performed in the intention-to-treat (ITT) population consisting of all patients randomized with at least one report on antibiotic use. For hypothesis (ii) to be tested, a covariance analysis of the log disease burden will be performed with the random group as factor and the day-0 (inclusion) log sum of symptom scores as covariate. Logarithms were chosen since the pilot study suggested that the distribution of disease burden was approximately normal after this transformation was applied. From this model, a two-sided 95% confidence interval for the ratio of the expected total disease burdens of conditional use vs. immediate use will be calculated by backtransformation (exponentiation) of the corresponding interval in log-units to the original scale. If this interval will lie entirely below 1.25, non-inferiority of conditional use therapy as compared to immediate use therapy can be stated. We pre-defined the margins of equivalence to be 80% to 125% as these margins are understood as minimum clinically relevant deviations. The analysis will be performed in the per protocol (PP) population consisting of all patients randomized with complete symptom score over 7 days and therapy in line with the study protocol. The analysis will be repeated in the ITT population to judge the validity of the per-protocol result.
7 Missing values will pose a serious challenge to the validity of the analysis since up to 15% premature study terminations due to non-compliance or withdrawal of consent are to be expected. For the ITT analyses, some kind of imputation of missing values in the co-primary endpoints is required. We thus decided to perform two ITT analyses for each endpoint. The primary analysis uses multiple imputations of missing values based on the available information. Last observation carried forward analysis will also be performed as an additional conservative sensitivity analysis. The technical details will be defined in a statistical analysis plan after a blind review of the data, before code break. Secondary endpoints will be analyzed by Mann Whitney-U-Tests tests (numbers) or analogous to the second co-primary endpoints, i.e. calculation of between-group differences or ratios with 95%-confidence limits, taking the different scale types into account. To characterise patients who will need antibiotic treatment in the conditional use group, an exploratory logistic regression analysis will be performed. Sample size The sample sizes required for the superiority and the non-inferiority part of the trial were based on the results of the pilot study, but were chosen rather conservative. For the superiority part, antibiotic prescription rates of 50% and 90% were assumed for conditional and immediate use, resulting in a sample size of 2x29 = 58 patients to yield a power of 90%. For the non-inferiority part, a coefficient of variation of 80% was assumed for disease burden, resulting in a sample size of 2x210 = 420 patients to reach a power of 90% for the case of zero group difference. Thus, the second hypothesis drives the sample size. With an assumed drop-out rate of 15% for the PP population, 494 patients have to be randomized. Calculations were done using PASS Safety At inclusion, patients will be instructed to reconsult at any time in case of ongoing/worsening symptoms. For this case, an immediate specific antibiotic therapy can be provided based on the urine culture at inclusion. Adverse events (AE) leading to practice consultation will be documented by the GP; minor AEs will be actively asked for during telephone interviews. Serious AE and patients reconsulting with fever will have to be reported immediately. An independent Data and Safety Monitoring Board is established to examine safety risks based on the safety related data regularly. Adverse events rates in both groups serve as safety outcomes and will be compared in data analysis. Late follow ups after 6 and 12 months serve to collect observational data of recurrences and other renal complications. Ethical considerations Ethical approval has been obtained by the Independent Ethics Committees of the Hannover Medical School (No M). The study will be conducted according to the principles of Good Clinical Practice.
8 Informed consent is taken by the GP who also ensures complete information about risks, benefits, and study procedures etc., based on a patient information sheet which is prepared according to current ethic committees standards. Patients can cancel their consent for the trial at any time without disadvantages. All data including patient identifiers will be treated confidentially. The patient declares her agreement to disclosure of pseudonymised data based on current data protection regulations. Registration This study is registered at clinical trials.gov (Nr ) with the acronym ICUTI. Discussion This study aims at investigating whether the use of antibiotics for uncomplicated UTI could be reduced by initial treatment with ibuprofen. The comparative effectiveness design was chosen to prove the effectiveness of two therapeutic strategies instead of the pure drug efficacy. This approach, fitting in the daily routines of UTI management in primary care , can eventually alter the way in which treatment of UTI is usually practiced. ICUTI is designed to create evidence for an alternative treatment option without antibiotics and to provide information about risks and benefits of both treatment strategies. While working out the study design, we considered different methodological approaches, one of which would have been a non-inferiority trial with a placebo-group . This could also have demonstrated the superiority of the other two treatment strategies over placebo, but we decided that these methodological benefits did not warrant withholding available treatments from patients who suffer from acute UTI. Therefore we decided against this approach. Many UTI trials focus on patients with microbiologically proven UTI. We decided to follow a more pragmatic approach by including patients presenting with typical symptoms. The resulting study population represents typical patients with uncomplicated lower UTI who are otherwise healthy. Urine cultures will only be provided for trial reasons on day 0 to assess bacterial count and species, to be able to discriminate patients with and without bacterial infections in the analysis, and to have data on resistance in case a secondary antibiotic treatment is needed. This is in line with general practitioners routine and general practice guidelines treatment decisions in uncomplicated UTI are usually made without microbiological specification. Procedures To optimize external validity, study-related changes of usual general practice procedures are minimized. Therefore, in line with routine GP procedures in primary care, study visits are restricted to inclusion on day 0. Further study visits are not mandatory. However, patients are instructed to return to see their doctor in case of persistent or recurrent symptoms, or if they wish to consult for other reasons.
9 Trial drug For immediate antibiotic therapy, fosfomycin-trometamol was chosen as first line treatment. The German UTI guideline recommends fosfomycin-trometamol as one of the first line treatment options [2,3], since its resistance rates with regard to E. coli are low  and symptoms are treated effectively. For UTI, a single dose treatment has been shown to be efficient, serving as comparator in other studies as well [22-24]. Considering symptom relief as the most important factor for UTI patients , we chose ibuprofen for the intervention group. Ibuprofen is known to be efficient for pain reduction in many conditions. It is safe and efficient for pain control and shows anti-inflammatory activity. Outcomes Studies on dose reduction or delayed treatment always have to address benefit and risk simultaneously. In this case, the benefit consists of a reduced number of antibiotic prescriptions, implying less resistance development and fewer side effects, whereas the potential risk of higher symptom burden has to be considered carefully. Therefore, we chose a combined primary endpoint with two components such as symptom course within 7 days and antibiotic usage up to day 28. Additionally, safety criteria will be assessed by several safety endpoints such as number of AE and SAE up to day 28. Safety Treatment courses are very short in both groups. Empirically, adverse drug effects should occur less frequently with ibuprofen than with antibiotic therapy. Complicated disease courses are not expected, since UTI is a non-serious condition. The risk of pyelonephritis after non-antibiotic treatment of UTI is often mentioned, but little data exists. In one trial comparing antibiotic versus placebo treatment in patients with UTI 1 of 38 patients treated with placebo was suspected to have a pyelonephritis [12,26]. To avoid safety risks, study patients are instructed to reconsult in case of persistent/worsening symptoms. Patients with fever have to be reported immediately. To assess a long-term-follow up, telephone interviews will be conducted after 6 and 12 months. Conclusions This trial may provide evidence for effectiveness for a new, non-antimicrobial treatment approach in general practice as indicated in the pilot study (HWI 01). If it could be shown that this strategy allows for a substantial reduction of antibiotics while being symptomatically effective and safe, treatment recommendations should be changed: anti-inflammatory agents as first choice therapy for uncomplicated UTI, and antibiotic treatment only for those who return with persisting or recurrent symptoms. Thus, the individual patient and society benefit from a reduced rate of antibiotic consumption reducing the pressure on resistance development.
10 Abbreviations AE, Adverse event; AIA, Activity Impairment Assessment; AUC, Area under Curve; CRF, Case report form; DDD, Daily defined dose; GP, General practice; ITT, Intention to treat; PP, Per protocol; RCT, Randomized clinical trial; SAE, Serious adverse event; UTI, Urinary tract infection Competing interests The authors have no conflicts of interest. Authors contributions EHP and MMK had the original idea for the study. IG, JB and GS will supervise the practices and manage the trial on a day-to day basis. Data analysis will be performed by KW. All authors read and approved the final manuscript. Acknowledgements The authors thank all GPs and practice staff for participation in this study. We thank the Institute for Clinical Research, Göttingen (IFS) for preparation of the trial (regulatory affairs and project management), the Pharmacy of the Charité (Berlin) and the Laboratory AMEDES Holding AG (Göttingen) for their cooperation. Funding The study is funded by the German Ministry of Research and Technology (Nr. 010KG1105) References 1. Scottish Intercollegiate Guidelines Network (SIGN: Management of suspected bacterial urinary tract infection in adults. A national clinical guideline. Edinburgh (Scotland): 2006 [http://www.sign.ac.uk/pdf/sign88.pdf (last access: February 21th 2012)]. 2. Wagenlehner FME, Schmiemann G, Hoyme U, Fünfstück R, Hummers-Pradier E, Kaase M, et al: Harnwegsinfektionen bei erwachsenen Patienten, unkomplizierte bakterielle ambulant erworbene: Epidemiologie, Diagnostik, Therapie und Management, S-3 Leitlinie der Arbeitsgemeinschaft Wissenschaftlicher Medizinischer Fachgesellschaften (AWMF).: (last access: February 21th 2012)]. 3. Schmiemann G, Gebhardt K, Matejczyk M, Hummers-Pradier E: DEGAM- Leitlinie Nr. 1: Brennen beim Wasserlassen Update 2009.:2009 (last access: February 21th 2012).
11 4. Ong DS, Kuyvenhoven MM, van Dijk L, Verheij TJ: Antibiotics for respiratory, ear and urinary tract disorders and consistency among GPs. J Antimicrob Chemother 2008, 62: Goossens H, Ferech M, Coenen S, Stephens P: Comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European countries. Clin Infect Dis 2007, 44: Hillier S, Roberts Z, Dunstan F, Butler C, Howard A, Palmer S: Prior antibiotics and risk of antibiotic-resistant community-acquired urinary tract infection: a case control study. J Antimicrob Chemother 2007, 60: Little P, Merriman R, Turner S, Rumsby K, Warner G, Lowes JA, et al: Presentation, pattern, and natural course of severe symptoms, and role of antibiotics and antibiotic resistance among patients presenting with suspected uncomplicated urinary tract infection in primary care: observational study. BMJ 2010, 340:b Butler CC, Dunstan F, Heginbothom M, Mason B, Roberts Z, Hillier S, et al: Containing antibiotic resistance: decreased antibiotic-resistant coliform urinary tract infections with reduction in antibiotic prescribing by general practices. Br J Gen Pract 2007, 57: Beerepoot MA, ter Riet G, Nys S, van der Wal WM, de Borgie CA, de Reijke TM, et al: Cranberries vs antibiotics to prevent urinary tract infections: a randomized doubleblind noninferiority trial in premenopausal women. Arch Intern Med 2011, 171: Patrick DM, Hutchinson J: Antibiotic use and population ecology: how you can reduce your "resistance footprint". CMAJ 2009, 180: Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD: Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ 2010, 340:c Christiaens TC, De Meyere M, Verschraegen G, Peersman W, Heytens S, De Maeseneer JM: Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br J Gen Pract 2002, 52: Ferry SA, Holm SE, Stenlund H, Lundholm R, Monsen TJ: The natural course of uncomplicated lower urinary tract infection in women illustrated by a randomized placebo controlled study. Scand J Infect Dis 2004, 36: Little P, Moore MV, Turner S, Rumsby K, Warner G, Lowes JA, et al: Effectiveness of five different approaches in management of urinary tract infection: randomised controlled trial. BMJ 2010, 340:c Bleidorn J, Gagyor I, Kochen MM, Wegscheider K, Hummers-Pradier E: Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection? results of a randomized controlled pilot trial. BMC Med 2010, 8:30.
12 16. Wild DJ, Clayson DJ, Keating K, Gondek K: Validation of a patient-administered questionnaire to measure the activity impairment experienced by women with uncomplicated urinary tract infection: the Activity Impairment Assessment (AIA). Health Qual Life Outcomes 2005, 3: Official ATC-Index for Germany Amtlicher ATC-Index mit DDD-Angaben für Deutschland (last access: February 21th 2012). 18. World Health Organization: Collaborating Centre for Drug Statistics Methodology. ATC Index with DDDs (last access: February 21th 2012). 19. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M: Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ 2008, 337:a Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ: Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006, 295: Knottnerus BJ, Nys S, ter Riet G, Donker G, Geerlings SE, Stobberingh E: Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands? J Antimicrob Chemother 2008, 62: Lobel B: Short term therapy for uncomplicated urinary tract infection today. Clinical outcome upholds the theories. Int J Antimicrob Agents 2003, 22(Suppl 2): Stein GE: Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther 1999, 21: Minassian MA, Lewis DA, Chattopadhyay D, Bovill B, Duckworth GJ, Williams JD: A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. Int J Antimicrob Agents 1998, 10: Hummers-Pradier E, Ohse AM, Koch M, Heizmann WR, Kochen MM: Management of urinary tract infections in female general practice patients. Fam Pract 2005, 22: Richards D, Toop L, Chambers S, Fletcher L: Response to antibiotics of women with symptoms of urinary tract infection but negative dipstick urine test results: double blind randomised controlled trial. BMJ 2005, 331:143.
DOI 10.1186/s40064-015-1505-6 RESEARCH Open Access Do general practitioners prescribe more antimicrobials when the weekend comes? Meera Tandan 1*, Sinead Duane 1 and Akke Vellinga 1,2 Abstract Inappropriate
for UTI: The Burning Question of Self Diagnosis Overview Review Pharmacist prescribing in Saskatchewan Discuss current management / diagnosis of UTI Appraise the literature for safe and accurate diagnosis
2012 Scottish Universities Medical Journal, Dundee Published online: July 2012 Electronically Published SUMJ 005 Stewart KE (2012). An Audit of Management of Acute Uncomplicated Lower UTI At a Health Centre
The Clinical Trial Protocol Guide 2011 BioStrategics Consulting Ltd. BioStrategics Consulting Ltd THE CLINICAL TRIAL PROTOCOL The clinical trial protocol to test one s product, to confirm or reject a specific
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
P a g e 1 PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain Clinical Phase 4 Study Centers Study Period 25 U.S. sites identified and reviewed by the Steering Committee and Contract
Family Practice Advance Access published December 7, 2013 Family Practice, 2013, Vol. 00, No. 00, 1 7 doi:10.1093/fampra/cmt077 Cystitis: antibiotic prescribing, consultation, attitudes and opinions Carmen
Awad Mohamed Ahmed, MD Professor of Medicine, University of Bahr Elghazal, Khartoum, Sudan For correspondence Professor Awad Mohamed Ahmed E-mail: email@example.com Tel.: +249 912344936 Abstract Randomized
Biostat Methods STAT 5820/6910 Handout #6: Intro. to Clinical Trials (Matthews text) Key features of RCT (randomized controlled trial) One group (treatment) receives its treatment at the same time another
A Phase 2 Study of (Avonex ) in Ulcerative Colitis - Study Results - ClinicalTrials.gov A Phase 2 Study of (Avonex ) in Ulcerative Colitis This study has been completed. Sponsor: Biogen Idec Information
CLINICAL AUDIT Appropriate Prescribing of Norfloxacin in Primary Care Valid to September 2013 bpac nz better medicin e Background Lower urinary tract infections [UTI] are a common problem in general practice.
POAC CLINICAL GUIDELINE Acute Pylonephritis DIAGNOSIS COMPLICATED PYELONEPHRITIS EXCLUSION CRITERIA: Male Known or suspected renal impairment (egfr < 60) Abnormality of renal tract Known or suspected renal
Improving the Diagnosis and Treatment of Urinary Tract Infection in family medicine, Systemic review 1 Rehab Ismail Mohammed Abdullah, 2 Taghreed Ismail Mohammed Abdullah Abstract: Background: Recurrent
Etiology and treatment of chronic bacterial prostatitis the Croatian experience Višnja Škerk University Hospital for Infectious Diseases "Dr. Fran Mihaljevic" Zagreb Croatia Milano, Malpensa, 14 Nov 2008
1.0 Abstract Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA Keywords Rationale and Background: This abbreviated clinical study report is based on a clinical surveillance
Version History Policy Title Drugs for MS.Drug facts box fingolimod Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required
Treatment of Common Pediatric Infections Medical Student Case Discussion Why are we talking about this? Antibiotic use is common: Estimated >30 million prescriptions to children annually 1 32 million pediatric
Febrile UTIs in Practice AAP Guidelines and New Evidence Jennifer Chapman, MD Kavita Parikh, MD, MSHS Shilpa Patel, MD, MPH Emergency Medicine Hospitalist Medicine Emergency Medicine June 15, 2016 Future
Antibiotic Prophylaxis for Short-term Catheter Bladder Drainage in adults A Systematic Review (Cochrane database August 2013) Gail Lusardi, Senior Lecturer Dr Allyson Lipp, Principal Lecturer, Dr Chris
These guidelines apply to all research projects where human subjects are involved in the study GUIDELINES FOR RESEARCHERS PATIENT INFORMATION SHEET & CONSENT FORM The guidance, which follows, applies primarily
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
HOMEOPATHY AS AN ALTERNATIVE TO ANTIBIOTICS Professor Dr. Michael FRASS Medical University of Vienna, Department Medicine I Doctor s Asscociation for Classical Homeopathy www.aekh.at President, Umbrella
* This presentation is prepared by the author in one s personal capacity for the purpose of academic exchange and does not represent the views of his/her organisations on the topic discussed. Journal Presentation
Title of critically appraised topic: Is probiotic use an effective adjuvant therapy to antibiotics in treatment of Clostridium difficile-associated diarrhea? Author: (This copy has been stripped of identifiers)
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
Shared Care Guideline for Prescription and monitoring of Acamprosate Calcium Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist, Alcohol Services Dr Donnelly
Oral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial Marcus R. Pereira A. Study Purpose Hepatic encephalopathy is a common complication
PRIORITY RESEARCH TOPICS Understanding all the issues associated with antimicrobial resistance is probably impossible, but it is clear that there are a number of key issues about which we need more information.
82 Urinary Tract Infection Update Kim Gibson, MD Joseph Toscano, MD Abstract Urinary tract infections are commonly treated in urgent care practice. Clinicians need to be aware of the advantages and limitations
TUTORIAL on ICH E9 and Other Statistical Regulatory Guidance Session 1: PSI Conference, May 2011 Kerry Gordon, Quintiles 1 E9, and how to locate it 2 ICH E9 Statistical Principles for Clinical Trials (Issued
Management of culture positive urinary tract infections in children aged 0-16 years: An audit conducted in a District General Hospital in the United Kingdom *S Jeyabalan 1, E. Ikpakwu 2, G Liyanage 3 Sri
CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto Bayer Inc.) New Indication: Pulmonary Embolism Note: The Canadian Drug Expert Committee (CDEC) previously reviewed rivaroxaban for the treatment of deep vein
Version History Policy Title Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
Outpatient Management of Urinary Tract Infections in Women Same Day Care Curriculum Development Project Paul R. Chelminski, MD, MPH, FACP Associate Residency Program Director Work In Progress Uncomplicated
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
General Remarks This template of a data extraction form is intended to help you to start developing your own data extraction form, it certainly has to be adapted to your specific question. Delete unnecessary
The legally binding text is the original French version TRANSPARENCY C OMMITTEE Opinion 20 November 2013 VOLTAFLEX 625 mg, film-coated tablet B/60 tablets (CIP: 34009 384 573 2) Applicant: NOVARTIS SANTÉ
Trial name: HOVON xxx yyy Sponsor: HOVON Version history Version number Version date Effective date 01 dd-mon-yyyy dd-mon-yyyy 02 dd-mon-yyyy dd-mon-yyyy 03 (current) dd-mon-yyyy dd-mon-yyyy QRMP authors
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
Article Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic T. Scott Stroup, M.D.,
Session 5: How to critically appraise a paper an example Appraising research broad questions l What is the research question? l Is the study ethical? l Is the study design valid and appropriate? l What
703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a
Mindanao Journal of Science and Technology Vol. 12 (2014) 171-178 Difference on the Incidence of Urinary Tract Infection (UTI) between Diabetic and Non-diabetic Women Admitted in Metro Cebu, Philippines
Clinical Trials in Palliative Care: Challenges and Opportunities Russell K. Portenoy, MD Chairman and Gerald J. and Dorothy R. Friedman Chair in Pain Medicine and Palliative Care Department of Pain Medicine
1 2 3 November 2010 EMA/759784/2010 Committee for Medicinal Products for Human Use 4 5 6 7 Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and
Research Article Drug Utilization and Evaluation of Cephalosporin s At Tertiary Care Teaching Hospital, Bangalore HS. Shekar 1*, HR. Chandrashekhar 2, M. Govindaraju 3, P. Venugopalreddy 1, Chikkalingiah
Version History Policy Title Drugs for MS.Drug facts box fampridine Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required
U.S. Scientific Update Aricept 23 mg Tablets Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc. Unmet Need in Moderate to Severe Alzheimer s Disease (AD) Ongoing clinical deterioration
URINARY TRACT INFECTIONS TO TREAT OR NOT TO TREAT Eddie Grace, Pharm.D.,BCPS,AQ-ID, AAHIVE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy October 20 th, 2011 Objectives
TO SEND OR NOT TO SEND? THE ROLE OF URINE CULTURES IN UNCOMPLICATED UTI Patricia Moriarty, MSN, FNP-BC, APRN June 3, 2016 OBJECTIVES 1. List the indications for a urine culture. 2. Define an uncomplicated
TEMPLATE DATA MANAGEMENT PLAN ICRIN (QM sub group) Version: XX Date: XXXXXXX Page 1 of 6 1.0 Document Ownership The Data Management Plan (DMP) will be initiated and subsequently owned by the Data Manager
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January
Patient information leaflet for Termination of Pregnancy (TOP) / Abortion Families Division Options available If you d like a large print, audio, Braille or a translated version of this leaflet then please
I CONGRESSO NAZIONALE BIAS 2009 29/30 APRILE 2009 ELI LILLY SESTO FIORENTINO (FI) MISSING DATA: THE POINT OF VIEW OF ETHICAL COMMITTEES Anna Chiara Frigo Department of Environmental Medicine and Public
Research Study Protocol Template (For clinical trials) Instructions This protocol template is a tool to facilitate the development of a research study protocol specifically designed for the investigator
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,
Research articles Antibiotics for the common cold: expectations of Germany s general population M S Faber (firstname.lastname@example.org) 1,2, K Heckenbach 1, E Velasco 1,3, T Eckmanns 1 1. Department for Infectious Disease
ANTIBIOTICS FROM HEAD TO TOE: PART 5 - URINARY TRACT INFECTIONS LAUREN HYNICKA, PHARM.D. ANTIBIOTICS FROM HEAD TO TOE: PART 5 - URINARY TRACT INFECTIONS ACTIVITY DESCRIPTION Antibiotic use in the safest
A Guide to Clinical Trials For young people with cancer and their parents Children s Cancer and Leukaemia Group www.cclg.org.uk Original booklet produced in conjunction with the CCLG Patient Advocacy Committee.
Issues Regarding Use of Placebo in MS Drug Trials Peter Scott Chin, MD Novartis Pharmaceuticals Corporation Context of the Guidance The draft EMA Guidance mentions placebo as a comparator for superiority
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
Preview: Post-class quiz 5 - Clinical Trials Question 1 What is meant by "randomization"? (Select the one best answer.) Question 2 A. Selection of subjects at random. B. Randomization is a method of allocating
Management of Otitis Media in Children Dong Soo Kim, M.D. Department of Pediatrics Yonsei University College of Medicine, Severance Hospital E mail : email@example.com Abstract Otitis media is
Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare
The importance of adherence and persistence: The advantages of once-daily dosing Craig I. Coleman, PharmD Professor, University of Connecticut School of Pharmacy Storrs, CT, USA Conflicts of interest Dr
Designing Economic Evaluations in Clinical Trials Henry Glick Institutt for helseledelse og helseøkonomi November 24, 2008 Good Value for the Cost Economic data collected as primary or secondary endpoints
Guidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998 Section I: Preamble The New Hampshire Medical Society believes that principles
URINARY TRACT INFECTIONS IN YOUNG WOMEN Reviewed by Finnish Centre for Health Promotion Publisher: Ylioppilaiden terveydenhoitosäätiö Töölönkatu 37 A 00260 Helsinki Orders: firstname.lastname@example.org Author:
FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C SR in Combination with an ERA and/or a PDE-5 Inhibitor
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by
(LY041001) These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or
1 REPORTING ON PARTICIPANT DISPOSITION IN CLINICAL TRIALS Dennis C. Turk, Ph.D. 1 University of Washington School of Medicine Running head: Patient Disposition 1 Preparation of this manuscript was supported
2.0 Synopsis Abbott Laboratories Name of Study Drug: Vicodin CR Name of Active Ingredient: Hydrocodone/Acetaminophen Extended Release (ABT-712) Individual Study Table Referring to Part of Dossier: Volume:
Guidelines used in the management of paediatric patients with urinary tract infections in University hospital Trnava Katarína Dudáková Kristína Grendová GLOBAL PUBLIC HEALTH ISSUES INTERNATIONAL COLLOQUIUM